obinutuzumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 4983 949142-50-1

Description:

MoleculeDescription

Synonyms:

  • gazyva
  • RO-5072759
  • RO 5072759
  • obinutuzumab
  • huMAB<CD20>
  • GA101
  • gazyvaro
anti-CD20 mAb for treating B-cell lymphoid cancers
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
35.70 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
July 2, 2018 PMDA Chugai Pharmaceutical Co., Ltd.
Nov. 1, 2013 FDA GENENTECH
July 23, 2014 EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
COVID-19 591.12 26.17 342 12679 168501 90446925
Neutropenia 551.63 26.17 363 12658 224541 90390885
Myelosuppression 483.58 26.17 207 12814 53384 90562042
Cytokine release syndrome 471.69 26.17 170 12851 27803 90587623
Febrile neutropenia 403.23 26.17 262 12759 158087 90457339
Off label use 339.60 26.17 581 12440 1101671 89513755
Thrombocytopenia 301.39 26.17 245 12776 208480 90406946
Disease progression 289.67 26.17 213 12808 156402 90459024
COVID-19 pneumonia 260.21 26.17 98 12923 18079 90597347
Tumour lysis syndrome 258.41 26.17 86 12935 11066 90604360
Pyrexia 221.71 26.17 363 12658 660122 89955304
Hypogammaglobulinaemia 195.36 26.17 69 12952 10605 90604821
Infusion related reaction 192.17 26.17 266 12755 416514 90198912
Chills 179.85 26.17 150 12871 131831 90483595
Neutrophil count decreased 159.05 26.17 109 12912 71423 90544003
Platelet count decreased 141.31 26.17 133 12888 136836 90478590
No adverse event 138.05 26.17 98 12923 67884 90547542
Cytopenia 117.47 26.17 55 12966 17394 90598032
Lymphocyte count decreased 111.59 26.17 67 12954 34983 90580443
Cytomegalovirus infection 109.16 26.17 60 12961 26542 90588884
Post-acute COVID-19 syndrome 103.83 26.17 26 12995 1211 90614215
Lymphoma 91.97 26.17 43 12978 13548 90601878
Agranulocytosis 84.10 26.17 56 12965 34946 90580480
White blood cell count decreased 75.68 26.17 106 12915 167003 90448423
B-cell lymphoma recurrent 75.22 26.17 17 13004 507 90614919
Temperature intolerance 72.06 26.17 35 12986 11995 90603431
Pneumonia 69.38 26.17 225 12796 637834 89977592
Pain 68.35 26.17 29 12992 996312 89619114
Pancytopenia 67.88 26.17 85 12936 120178 90495248
Tumour flare 62.58 26.17 15 13006 581 90614845
Blood lactate dehydrogenase increased 61.11 26.17 41 12980 25891 90589535
Joint swelling 59.95 26.17 3 13018 503297 90112129
Haematotoxicity 59.05 26.17 31 12990 12504 90602922
Lymphoma transformation 58.88 26.17 12 13009 216 90615210
Chest discomfort 58.55 26.17 85 12936 138280 90477146
Lymphadenopathy 58.07 26.17 50 12971 45725 90569701
Chronic lymphocytic leukaemia recurrent 57.58 26.17 13 13008 386 90615040
Cytomegalovirus chorioretinitis 57.39 26.17 19 13002 2400 90613026
Apoptotic colonopathy 56.86 26.17 10 13011 77 90615349
Pneumonitis 55.53 26.17 48 12973 44122 90571304
Measles 52.37 26.17 12 13009 381 90615045
Cytomegalovirus infection reactivation 50.68 26.17 24 12997 7776 90607650
Progressive multifocal leukoencephalopathy 50.00 26.17 30 12991 15625 90599801
Condition aggravated 48.27 26.17 13 13008 595532 90019894
Anaemia 47.22 26.17 134 12887 352668 90262758
Alopecia 45.80 26.17 8 13013 495063 90120363
B-lymphocyte abnormalities 45.56 26.17 10 13011 260 90615166
Hypertensive cardiomyopathy 44.38 26.17 10 13011 294 90615132
Blood immunoglobulin G decreased 43.19 26.17 17 13004 3521 90611905
Follicular lymphoma 41.85 26.17 10 13011 382 90615044
Abdominal discomfort 41.44 26.17 9 13012 477319 90138107
Pneumocystis jirovecii pneumonia 41.17 26.17 30 12991 21586 90593840
Swelling 40.49 26.17 6 13015 419052 90196374
Listeria sepsis 40.20 26.17 11 13010 725 90614701
CD4 lymphocytes decreased 40.12 26.17 13 13008 1534 90613892
Coronavirus infection 39.02 26.17 18 13003 5497 90609929
Vaccination failure 38.96 26.17 12 13009 1201 90614225
Atrial fibrillation 38.57 26.17 69 12952 133542 90481884
Neutropenic infection 38.13 26.17 13 13008 1796 90613630
Aplasia pure red cell 36.90 26.17 17 13004 5177 90610249
Encephalitis enteroviral 36.77 26.17 7 13014 87 90615339
Obliterative bronchiolitis 36.70 26.17 14 13007 2667 90612759
Hepatitis B 35.93 26.17 16 13005 4503 90610923
Leukopenia 35.69 26.17 57 12964 100653 90514773
Hyperpyrexia 35.13 26.17 16 13005 4745 90610681
Hypotension 33.65 26.17 113 12908 325284 90290142
Blood disorder 33.13 26.17 18 13003 7772 90607654
Oxygen saturation decreased 32.95 26.17 57 12964 107426 90508000
Serum sickness 32.92 26.17 14 13007 3528 90611898
Drug specific antibody present 32.89 26.17 16 13005 5498 90609928
Nasopharyngitis 32.74 26.17 9 13012 407095 90208331
Contraindicated product administered 32.30 26.17 4 13017 320135 90295291
Blood pressure decreased 31.64 26.17 46 12975 74849 90540577
Diffuse large B-cell lymphoma 31.38 26.17 18 13003 8627 90606799
Varicella 30.94 26.17 12 13009 2390 90613036
Urinary tract infection bacterial 30.91 26.17 16 13005 6269 90609157
Sepsis 30.86 26.17 75 12946 179739 90435687
Retroperitoneal lymphadenopathy 30.82 26.17 9 13012 751 90614675
Weight increased 30.47 26.17 11 13010 417916 90197510
Respiratory failure 30.21 26.17 58 12963 118360 90497066
Fatigue 30.05 26.17 77 12944 1153946 89461480
Meningitis enteroviral 29.52 26.17 5 13016 30 90615396
Borrelia infection 28.61 26.17 7 13014 296 90615130
Second primary malignancy 28.34 26.17 18 13003 10360 90605066
Hypertransaminasaemia 27.97 26.17 21 13000 15804 90599622
Arthralgia 27.93 26.17 43 12978 778479 89836947
Aspergillus infection 27.65 26.17 18 13003 10805 90604621
Chronic lymphocytic leukaemia refractory 27.64 26.17 5 13016 46 90615380
Bronchopulmonary aspergillosis 26.80 26.17 18 13003 11380 90604046
Therapeutic product effect decreased 26.73 26.17 4 13017 277567 90337859
Humoral immune defect 26.68 26.17 7 13014 393 90615033

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
COVID-19 592.37 20.64 460 18973 115488 42486414
Infusion related reaction 588.40 20.64 358 19075 60448 42541454
Myelosuppression 429.33 20.64 253 19180 40208 42561694
Cytokine release syndrome 359.52 20.64 234 19199 44293 42557609
Tumour lysis syndrome 351.60 20.64 181 19252 22050 42579852
Disease progression 336.80 20.64 369 19064 143287 42458615
COVID-19 pneumonia 321.80 20.64 169 19264 21444 42580458
Neutropenia 305.64 20.64 413 19020 199018 42402884
Chills 284.03 20.64 277 19156 93789 42508113
Off label use 274.24 20.64 768 18665 637567 41964335
Hypogammaglobulinaemia 254.31 20.64 119 19314 11772 42590130
Febrile neutropenia 253.55 20.64 364 19069 185339 42416563
No adverse event 169.06 20.64 141 19292 38880 42563022
Pyrexia 168.75 20.64 475 18958 393567 42208335
Lymphocyte count decreased 115.28 20.64 98 19335 27711 42574191
End stage renal disease 111.83 20.64 78 19355 16480 42585422
Blood immunoglobulin G decreased 99.28 20.64 38 19395 2276 42599626
Blood lactate dehydrogenase increased 94.21 20.64 85 19348 25996 42575906
Chronic lymphocytic leukaemia recurrent 89.94 20.64 26 19407 642 42601260
Drug interaction 87.07 20.64 10 19423 266989 42334913
Neutrophil count decreased 77.07 20.64 118 19315 63297 42538605
Lymphadenopathy 76.58 20.64 85 19348 33280 42568622
Bronchopulmonary aspergillosis 75.49 20.64 66 19367 19363 42582539
Cytopenia 73.18 20.64 62 19371 17435 42584467
Post-acute COVID-19 syndrome 72.30 20.64 20 19413 419 42601483
Basal cell carcinoma 72.26 20.64 69 19364 22664 42579238
Thrombocytopenia 71.93 20.64 220 19213 190059 42411843
Cytomegalovirus infection 71.91 20.64 81 19352 32225 42569677
Pneumonia 71.87 20.64 380 19053 421769 42180133
Condition aggravated 65.31 20.64 19 19414 260735 42341167
Toxicity to various agents 64.60 20.64 13 19420 229123 42372779
B-cell lymphoma recurrent 62.95 20.64 21 19412 841 42601061
Lymphoma transformation 59.77 20.64 18 19415 514 42601388
Brain abscess 59.46 20.64 32 19401 4252 42597650
Organic brain syndrome 58.17 20.64 16 19417 328 42601574
Product dose omission issue 58.03 20.64 3 19430 154362 42447540
Coronavirus infection 56.21 20.64 33 19400 5181 42596721
Lymphocyte count increased 55.41 20.64 30 19403 4034 42597868
Squamous cell carcinoma 52.24 20.64 45 19388 12937 42588965
Chest discomfort 51.67 20.64 99 19334 63517 42538385
Platelet count decreased 50.23 20.64 158 19275 138423 42463479
Urge incontinence 50.05 20.64 16 19417 559 42601343
Fatigue 50.01 20.64 76 19357 435565 42166337
Organising pneumonia 49.72 20.64 35 19398 7497 42594405
Mantle cell lymphoma refractory 47.86 20.64 11 19422 104 42601798
Cytomegalovirus chorioretinitis 46.62 20.64 28 19405 4583 42597319
Bacillus infection 45.96 20.64 16 19417 730 42601172
Ill-defined disorder 45.33 20.64 46 19387 16250 42585652
Cerebral aspergillosis 44.94 20.64 20 19413 1757 42600145
Progressive multifocal leukoencephalopathy 44.42 20.64 39 19394 11497 42590405
Immune effector cell-associated neurotoxicity syndrome 42.61 20.64 35 19398 9426 42592476
Flushing 42.30 20.64 67 19366 36961 42564941
Bacillus bacteraemia 42.26 20.64 11 19422 181 42601721
Bladder hypertrophy 41.62 20.64 15 19418 758 42601144
Hypersensitivity 40.70 20.64 97 19336 72273 42529629
Temperature intolerance 40.61 20.64 26 19407 4762 42597140
Diffuse large B-cell lymphoma 40.55 20.64 34 19399 9420 42592482
Arthralgia 38.43 20.64 23 19410 205215 42396687
Somnolence 37.71 20.64 9 19424 141096 42460806
Intentional product use issue 36.90 20.64 93 19340 71740 42530162
Opportunistic infection 36.60 20.64 18 19415 1983 42599919
Tumour flare 35.80 20.64 15 19418 1138 42600764
Splenomegaly 34.98 20.64 41 19392 17006 42584896
Insomnia 34.80 20.64 6 19427 118247 42483655
Retinitis viral 34.25 20.64 9 19424 154 42601748
Febrile infection 33.77 20.64 19 19414 2752 42599150
Follicular lymphoma 32.94 20.64 11 19422 442 42601460
Oral fungal infection 32.17 20.64 16 19417 1805 42600097
Blood immunoglobulin A decreased 31.86 20.64 12 19421 687 42601215
Vena cava thrombosis 31.44 20.64 15 19418 1546 42600356
Pruritus allergic 30.84 20.64 10 19423 366 42601536
Weight increased 30.65 20.64 6 19427 107977 42493925
Histoplasmosis disseminated 30.08 20.64 16 19417 2075 42599827
Overdose 29.56 20.64 6 19427 105258 42496644
Atrial fibrillation 29.54 20.64 134 19299 139459 42462443
Fall 28.71 20.64 39 19394 234481 42367421
Diffuse large B-cell lymphoma recurrent 28.35 20.64 21 19412 4865 42597037
White blood cell count decreased 28.01 20.64 112 19321 110284 42491618
Diffuse large B-cell lymphoma refractory 27.94 20.64 15 19418 1982 42599920
Gallbladder polyp 27.87 20.64 10 19423 499 42601403
Infection 27.09 20.64 112 19321 111956 42489946
Gait disturbance 26.67 20.64 6 19427 97994 42503908
Oxygen saturation decreased 26.44 20.64 77 19356 64610 42537292
Pancytopenia 26.39 20.64 115 19318 117628 42484274
Anaphylactic shock 24.74 20.64 41 19392 23476 42578426
Adjustment disorder 24.33 20.64 12 19421 1330 42600572
Necrotising retinitis 24.16 20.64 11 19422 1019 42600883
Cytomegalovirus enterocolitis 23.99 20.64 12 19421 1371 42600531
Meningitis enteroviral 23.90 20.64 5 19428 29 42601873
Acute myeloid leukaemia 23.68 20.64 39 19394 22217 42579685
Hypotension 23.54 20.64 199 19234 257432 42344470
Pneumonitis 23.53 20.64 56 19377 41662 42560240
Cataract subcapsular 23.12 20.64 9 19424 564 42601338
Agranulocytosis 22.85 20.64 46 19387 30566 42571336
Secondary immunodeficiency 22.83 20.64 10 19423 846 42601056
Headache 22.64 20.64 47 19386 239322 42362580
Peroneal nerve palsy 22.48 20.64 16 19417 3486 42598416
Lymphoma 22.29 20.64 30 19403 14291 42587611
Epididymitis 22.14 20.64 15 19418 3019 42598883
Erysipelas 21.70 20.64 20 19413 6276 42595626
Bacterial disease carrier 21.50 20.64 9 19424 681 42601221
Abdominal neoplasm 21.34 20.64 8 19425 452 42601450
Therapy partial responder 21.18 20.64 35 19398 19986 42581916
Constipation 20.86 20.64 26 19407 162265 42439637
Cardiac disorder 20.72 20.64 59 19374 48873 42553029

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
COVID-19 1222.61 21.53 774 28331 244286 110315908
Myelosuppression 870.09 21.53 446 28659 93894 110466300
Cytokine release syndrome 789.21 21.53 380 28725 69926 110490268
Neutropenia 700.80 21.53 661 28444 373959 110186235
Febrile neutropenia 654.34 21.53 591 28514 316176 110244018
COVID-19 pneumonia 607.16 21.53 261 28844 36882 110523312
Tumour lysis syndrome 521.72 21.53 222 28883 30579 110529615
Hypogammaglobulinaemia 460.91 21.53 180 28925 19896 110540298
Off label use 450.76 21.53 1119 27986 1499066 109061128
Infusion related reaction 449.03 21.53 526 28579 380636 110179558
Chills 443.58 21.53 381 28724 190199 110369995
Disease progression 429.46 21.53 417 28688 243617 110316577
Pyrexia 377.02 21.53 767 28338 897498 109662696
Thrombocytopenia 280.64 21.53 399 28706 348486 110211708
Neutrophil count decreased 218.59 21.53 210 28895 120731 110439463
No adverse event 199.20 21.53 161 28944 73678 110486516
Cytopenia 195.39 21.53 113 28992 30003 110530191
Pneumonia 195.00 21.53 588 28517 876126 109684068
Lymphocyte count decreased 191.91 21.53 142 28963 57101 110503093
Post-acute COVID-19 syndrome 175.80 21.53 47 29058 1528 110558666
Cytomegalovirus infection 175.68 21.53 132 28973 54312 110505882
Platelet count decreased 173.97 21.53 256 28849 230187 110330007
Blood lactate dehydrogenase increased 146.39 21.53 109 28996 44225 110515969
Blood immunoglobulin G decreased 140.26 21.53 53 29052 5347 110554847
End stage renal disease 132.48 21.53 78 29027 21395 110538799
Bronchopulmonary aspergillosis 127.73 21.53 86 29019 29777 110530417
Condition aggravated 117.74 21.53 25 29080 734811 109825383
Temperature intolerance 111.35 21.53 60 29045 13890 110546304
Lymphadenopathy 109.90 21.53 108 28997 63727 110496467
Drug interaction 107.38 21.53 6 29099 500177 110060017
Joint swelling 102.79 21.53 3 29102 442842 110117352
Coronavirus infection 99.11 21.53 49 29056 9496 110550698
Cytomegalovirus chorioretinitis 96.73 21.53 44 29061 7084 110553110
Agranulocytosis 94.44 21.53 98 29007 61662 110498532
Chronic lymphocytic leukaemia recurrent 92.46 21.53 26 29079 1023 110559171
Progressive multifocal leukoencephalopathy 90.62 21.53 65 29040 24891 110535303
Chest discomfort 86.28 21.53 160 28945 173688 110386506
White blood cell count decreased 85.07 21.53 187 28918 229203 110330991
Pain 84.96 21.53 76 29029 954879 109605315
Pancytopenia 82.44 21.53 175 28930 209438 110350756
Basal cell carcinoma 82.44 21.53 79 29026 45191 110515003
Lymphoma transformation 81.72 21.53 21 29084 583 110559611
B-cell lymphoma recurrent 81.11 21.53 24 29081 1134 110559060
Arthralgia 80.84 21.53 53 29052 779579 109780615
Atrial fibrillation 79.33 21.53 182 28923 229460 110330734
Lymphoma 76.61 21.53 54 29051 20117 110540077
Squamous cell carcinoma 76.16 21.53 52 29053 18411 110541783
Immune effector cell-associated neurotoxicity syndrome 74.03 21.53 47 29058 14735 110545459
Tumour flare 73.95 21.53 24 29081 1543 110558651
Alopecia 73.50 21.53 6 29099 364747 110195447
Organising pneumonia 73.11 21.53 46 29059 14197 110545997
Fatigue 72.63 21.53 131 28974 1215827 109344367
Pneumonitis 66.46 21.53 91 29014 76440 110483754
Weight increased 63.69 21.53 16 29089 419628 110140566
Musculoskeletal stiffness 61.13 21.53 3 29102 279819 110280375
Nasopharyngitis 59.91 21.53 15 29090 394346 110165848
Sepsis 58.24 21.53 204 28901 327142 110233052
Cytomegalovirus infection reactivation 58.11 21.53 44 29061 18289 110541905
Product dose omission issue 57.91 21.53 8 29097 321774 110238420
Swelling 56.01 21.53 12 29093 351029 110209165
Oxygen saturation decreased 55.94 21.53 126 28979 156856 110403338
Diffuse large B-cell lymphoma recurrent 55.66 21.53 29 29076 6270 110553924
Hypotension 55.18 21.53 278 28827 523571 110036623
Brain abscess 53.68 21.53 29 29076 6745 110553449
Toxicity to various agents 53.47 21.53 30 29075 480525 110079669
Headache 52.64 21.53 95 29010 882282 109677912
Abdominal discomfort 52.54 21.53 19 29086 393839 110166355
Insomnia 52.34 21.53 15 29090 360575 110199619
Interstitial lung disease 52.08 21.53 114 28991 139220 110420974
Mantle cell lymphoma refractory 51.57 21.53 11 29094 131 110560063
Cerebral aspergillosis 50.55 21.53 20 29085 2282 110557912
Neutropenic infection 50.34 21.53 22 29083 3223 110556971
Follicular lymphoma 50.06 21.53 15 29090 740 110559454
Aplasia pure red cell 49.33 21.53 31 29074 9547 110550647
Meningitis enteroviral 49.23 21.53 10 29095 92 110560102
Haematotoxicity 48.59 21.53 42 29063 21040 110539154
Opportunistic infection 48.48 21.53 22 29083 3521 110556673
Blister 47.92 21.53 3 29102 227373 110332821
Diffuse large B-cell lymphoma 47.85 21.53 37 29068 15861 110544333
Contraindicated product administered 47.55 21.53 5 29100 248262 110311932
Apoptotic colonopathy 47.34 21.53 11 29094 198 110559996
Pneumocystis jirovecii pneumonia 46.79 21.53 57 29048 42678 110517516
Febrile infection 46.67 21.53 23 29082 4425 110555769
Pain in extremity 46.62 21.53 36 29069 487082 110073112
Therapeutic product effect decreased 46.59 21.53 5 29100 244311 110315883
Septic shock 45.94 21.53 117 28988 157411 110402783
Fall 45.69 21.53 55 29050 603427 109956767
Vaccination failure 45.52 21.53 19 29086 2487 110557707
Pemphigus 44.72 21.53 3 29102 214567 110345627
Hyperpyrexia 43.79 21.53 27 29078 8042 110552152
Respiratory tract infection 43.40 21.53 72 29033 71545 110488649
Measles 43.06 21.53 13 29092 658 110559536
Neutropenic sepsis 42.06 21.53 46 29059 30700 110529494
Cytomegalovirus enterocolitis 40.45 21.53 17 29088 2264 110557930
Flushing 39.48 21.53 86 29019 104650 110455544
Myelodysplastic syndrome 39.43 21.53 49 29056 37435 110522759
Contusion 39.27 21.53 7 29098 233354 110326840
CD4 lymphocytes decreased 39.23 21.53 18 29087 2956 110557238
Asthma 39.01 21.53 9 29096 250282 110309912
Hypoaesthesia 38.88 21.53 17 29088 314206 110245988
Obliterative bronchiolitis 38.32 21.53 19 29086 3704 110556490
Serum sickness 38.12 21.53 20 29085 4386 110555808
Overdose 37.26 21.53 8 29097 233786 110326408
Retroperitoneal lymphadenopathy 36.95 21.53 14 29091 1422 110558772
Lymphocytosis 36.94 21.53 21 29084 5390 110554804
Hypoxia 36.52 21.53 95 29010 129420 110430774
Gait disturbance 36.12 21.53 14 29091 278194 110282000
Organic brain syndrome 36.08 21.53 11 29094 576 110559618
Immune system disorder 35.45 21.53 29 29076 13472 110546722
Somnolence 35.39 21.53 17 29088 297432 110262762
Herpes zoster 35.30 21.53 84 29021 108295 110451899
Impaired healing 35.12 21.53 5 29100 196712 110363482
Anxiety 34.96 21.53 24 29081 345054 110215140
Leukopenia 34.88 21.53 102 29003 148689 110411505
Bacillus bacteraemia 34.81 21.53 9 29096 256 110559938
Inflammation 34.30 21.53 5 29100 193233 110366961
Acute myeloid leukaemia 34.11 21.53 46 29059 38064 110522130
Migraine 34.07 21.53 3 29102 171649 110388545
Respiratory failure 33.87 21.53 129 28976 215203 110344991
Memory impairment 32.93 21.53 6 29099 196938 110363256
Anaphylactic shock 32.82 21.53 53 29052 51493 110508701
Listeria sepsis 32.38 21.53 11 29094 815 110559379
Oral fungal infection 32.35 21.53 18 29087 4434 110555760
Colitis 31.93 21.53 78 29027 102245 110457949
Bacillus infection 31.90 21.53 13 29092 1601 110558593
Second primary malignancy 31.88 21.53 31 29074 18037 110542157
Lymphocyte count increased 31.41 21.53 21 29084 7182 110553012
Feeling abnormal 31.33 21.53 5 29100 180706 110379488
Bone marrow failure 30.90 21.53 55 29050 57793 110502401
Splenomegaly 30.67 21.53 35 29070 24463 110535731
Peripheral swelling 30.36 21.53 37 29068 403997 110156197
Urge incontinence 30.05 21.53 12 29093 1403 110558791
Blood pressure decreased 30 21.53 82 29023 115009 110445185
Retinitis viral 29.92 21.53 9 29096 450 110559744
Blood disorder 29.89 21.53 23 29082 9787 110550407
Dyspepsia 29.49 21.53 7 29098 190958 110369236
Discomfort 29.23 21.53 10 29095 214697 110345497
Cardiac disorder 29.16 21.53 63 29042 76217 110483977
Histoplasmosis disseminated 28.98 21.53 16 29089 3883 110556311
Borrelia infection 28.69 21.53 8 29097 305 110559889
Wheezing 28.26 21.53 16 29089 255214 110304980
Aspergillus infection 27.77 21.53 34 29071 25582 110534612
Drug intolerance 27.71 21.53 40 29065 406472 110153722
Therapy partial responder 27.64 21.53 41 29064 37020 110523174
Treatment failure 27.13 21.53 20 29085 277214 110282980
Inappropriate schedule of product administration 26.84 21.53 10 29095 203627 110356567
Epididymitis 26.53 21.53 13 29092 2471 110557723
Type 2 diabetes mellitus 26.40 21.53 7 29098 177225 110382969
Bacteraemia 26.19 21.53 43 29062 42347 110517847
Aspartate aminotransferase increased 26.13 21.53 97 29008 159839 110400355
Drug hypersensitivity 26.02 21.53 50 29055 454040 110106154
Erysipelas 25.93 21.53 24 29081 13134 110547060
Tachypnoea 25.75 21.53 41 29064 39354 110520840
Pneumonia bacterial 25.51 21.53 33 29072 26228 110533966
Bladder hypertrophy 25.50 21.53 10 29095 1114 110559080
Malaise 25.49 21.53 91 29014 671728 109888466
Gastrooesophageal reflux disease 25.17 21.53 8 29097 179968 110380226
Vena cava thrombosis 25.04 21.53 14 29091 3480 110556714
Encephalitis enteroviral 25.00 21.53 7 29098 271 110559923
Blood immunoglobulin A decreased 24.71 21.53 12 29093 2236 110557958
Intentional product misuse 24.63 21.53 3 29102 132901 110427293
Gallbladder polyp 24.19 21.53 10 29095 1277 110558917
Psoriasis 23.98 21.53 4 29101 139989 110420205
Hepatitis B 23.89 21.53 20 29085 9592 110550602
Anaemia 23.76 21.53 234 28871 546852 110013342
Abdominal pain upper 23.16 21.53 35 29070 349076 110211118
Cytomegalovirus test positive 22.55 21.53 17 29088 7019 110553175
Arthritis 22.47 21.53 8 29097 167578 110392616
Hospitalisation 22.45 21.53 5 29100 142488 110417706
Squamous cell carcinoma of skin 22.25 21.53 25 29080 17178 110543016
Necrotising retinitis 22.12 21.53 10 29095 1586 110558608
Therapeutic product effect incomplete 22.08 21.53 16 29089 223789 110336405
Febrile bone marrow aplasia 21.94 21.53 25 29080 17440 110542754
Malignant neoplasm of orbit 21.81 21.53 4 29101 20 110560174
Humoral immune defect 21.78 21.53 8 29097 745 110559449
Pruritus allergic 21.59 21.53 10 29095 1678 110558516

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FA03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
CD20 (Clusters of Differentiation 20) inhibitors
FDA MoA N0000175078 CD20-directed Antibody Interactions
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000970 Antineoplastic Agents
FDA EPC N0000175657 CD20-directed Cytolytic Antibody
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:231911 renoprotective agent

Related Drugs by ATC class:

L01FA CD20 (Clusters of Differentiation 20) inhibitors 2 drugs
ofatumumabrituximab

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
CD20-positive follicular lymphoma indication 55150002
Chronic lymphoid leukemia, disease indication 92814006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
B-lymphocyte antigen CD20 Surface antigen ANTIBODY BINDING DRUG LABEL DRUG LABEL

External reference:

IDSource
D09321 KEGG_DRUG
4032842 VUID
N0000189499 NUI
4032842 VANDF
CHEBI:750126 CHEBI
CHEMBL1743048 ChEMBL_ID
C543332 MESH_SUPPLEMENTAL_RECORD_UI
6941 IUPHAR_LIGAND_ID
DB08935 DRUGBANK_ID
1442694 RXNORM
206788 MMSL
29767 MMSL
d08134 MMSL
015268 NDDF
710287009 SNOMEDCT_US
715547003 SNOMEDCT_US
C2742503 UMLSCUI
9043 INN_ID
O43472U9X8 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Gazyva HUMAN PRESCRIPTION DRUG LABEL 1 50242-070 INJECTION, SOLUTION, CONCENTRATE 1000 mg INTRAVENOUS BLA 31 sections
Gazyva HUMAN PRESCRIPTION DRUG LABEL 1 50242-070 INJECTION, SOLUTION, CONCENTRATE 1000 mg INTRAVENOUS BLA 31 sections